glp 1 compounding fda Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP-1 while @martymakary is photographed holding bootleg # The FDA's GLP-1 Compounding Crackdown

Although Sofwave is still relatively new (it launched in 2015), it already boasts several FDA clearances

Its worth knowing theyre cash pay only, so insurance isnt part of the picture here

Retatrutide definitely hits harder, though Mazdutide was gentler overall

This makes it a more favorable option from a safety standpoint, particularly for patients who are newly diagnosed and whose medication regimen is still being established

Effects of Retatrutide on Body Weight Percent change in body weight at 80 weeks (primary endpoint) showed a dose response

In addition to POMC, other markers in the ARC that potentially represent targets for GLP-1RAs are currently being studied